These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 32770595)

  • 1. Development of a T-cell receptor mimic antibody targeting a novel Wilms tumor 1-derived peptide and analysis of its specificity.
    Kurosawa N; Midorikawa A; Ida K; Fudaba YW; Isobe M
    Cancer Sci; 2020 Oct; 111(10):3516-3526. PubMed ID: 32770595
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Generation and evaluation of cancer binding capacity of HLA-A2-WT1 complex-targeting antibody.
    Yao X; Matosevic S
    Immunol Lett; 2024 Aug; 268():106881. PubMed ID: 38810886
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Antitumor Activity of TCR-Mimic Antibody-Drug Conjugates (TCRm-ADCs) Targeting the Intracellular Wilms Tumor 1 (WT1) Oncoprotein.
    Shen Y; Li YM; Zhou JJ; Zhou Z; Xu YC; Zhao WB; Chen SQ
    Int J Mol Sci; 2019 Aug; 20(16):. PubMed ID: 31408937
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A High-avidity WT1-reactive T-Cell Receptor Mediates Recognition of Peptide and Processed Antigen but not Naturally Occurring WT1-positive Tumor Cells.
    Jaigirdar A; Rosenberg SA; Parkhurst M
    J Immunother; 2016 Apr; 39(3):105-16. PubMed ID: 26938944
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Affinity maturation of T-cell receptor-like antibodies for Wilms tumor 1 peptide greatly enhances therapeutic potential.
    Zhao Q; Ahmed M; Tassev DV; Hasan A; Kuo TY; Guo HF; O'Reilly RJ; Cheung NK
    Leukemia; 2015 Nov; 29(11):2238-47. PubMed ID: 25987253
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TCR mimic monoclonal antibody targets a specific peptide/HLA class I complex and significantly impedes tumor growth in vivo using breast cancer models.
    Verma B; Neethling FA; Caseltine S; Fabrizio G; Largo S; Duty JA; Tabaczewski P; Weidanz JA
    J Immunol; 2010 Feb; 184(4):2156-65. PubMed ID: 20065111
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimized T-cell receptor-mimic chimeric antigen receptor T cells directed toward the intracellular Wilms Tumor 1 antigen.
    Rafiq S; Purdon TJ; Daniyan AF; Koneru M; Dao T; Liu C; Scheinberg DA; Brentjens RJ
    Leukemia; 2017 Aug; 31(8):1788-1797. PubMed ID: 27924074
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High throughput development of TCR-mimic antibody that targets survivin-2B
    Kurosawa N; Wakata Y; Ida K; Midorikawa A; Isobe M
    Sci Rep; 2019 Jul; 9(1):9827. PubMed ID: 31285464
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comprehensive mutagenesis identifies the peptide repertoire of a p53 T-cell receptor mimic antibody that displays no toxicity in mice transgenic for human HLA-A*0201.
    Trenevska I; Anderson AP; Bentley C; Hassanali T; Wiblin S; Maguire S; Pezzella F; Banham AH; Li D
    PLoS One; 2021; 16(4):e0249967. PubMed ID: 33836029
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting intracellular WT1 in AML with a novel RMF-peptide-MHC-specific T-cell bispecific antibody.
    Augsberger C; Hänel G; Xu W; Pulko V; Hanisch LJ; Augustin A; Challier J; Hunt K; Vick B; Rovatti PE; Krupka C; Rothe M; Schönle A; Sam J; Lezan E; Ducret A; Ortiz-Franyuti D; Walz AC; Benz J; Bujotzek A; Lichtenegger FS; Gassner C; Carpy A; Lyamichev V; Patel J; Konstandin N; Tunger A; Schmitz M; von Bergwelt-Baildon M; Spiekermann K; Vago L; Jeremias I; Marrer-Berger E; Umaña P; Klein C; Subklewe M
    Blood; 2021 Dec; 138(25):2655-2669. PubMed ID: 34280257
    [TBL] [Abstract][Full Text] [Related]  

  • 11. T-cell Receptors Engineered
    Sharma P; Harris DT; Stone JD; Kranz DM
    Cancer Immunol Res; 2019 Dec; 7(12):2025-2035. PubMed ID: 31548259
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessing vaccine potency using TCRmimic antibodies.
    Neethling FA; Ramakrishna V; Keler T; Buchli R; Woodburn T; Weidanz JA
    Vaccine; 2008 Jun; 26(25):3092-102. PubMed ID: 18353510
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of a Titin-derived HLA-A1-presented peptide as a cross-reactive target for engineered MAGE A3-directed T cells.
    Cameron BJ; Gerry AB; Dukes J; Harper JV; Kannan V; Bianchi FC; Grand F; Brewer JE; Gupta M; Plesa G; Bossi G; Vuidepot A; Powlesland AS; Legg A; Adams KJ; Bennett AD; Pumphrey NJ; Williams DD; Binder-Scholl G; Kulikovskaya I; Levine BL; Riley JL; Varela-Rohena A; Stadtmauer EA; Rapoport AP; Linette GP; June CH; Hassan NJ; Kalos M; Jakobsen BK
    Sci Transl Med; 2013 Aug; 5(197):197ra103. PubMed ID: 23926201
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of a TCR-like antibody and chimeric antigen receptor against NY-ESO-1/HLA-A2 for cancer immunotherapy.
    Liu X; Xu Y; Xiong W; Yin B; Huang Y; Chu J; Xing C; Qian C; Du Y; Duan T; Wang HY; Zhang N; Yu JS; An Z; Wang R
    J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35338087
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Allogeneic HLA-A*02-restricted WT1-specific T cells from mismatched donors are highly reactive but show off-target promiscuity.
    Falkenburg WJ; Melenhorst JJ; van de Meent M; Kester MG; Hombrink P; Heemskerk MH; Hagedoorn RS; Gostick E; Price DA; Falkenburg JH; Barrett AJ; Jedema I
    J Immunol; 2011 Sep; 187(5):2824-33. PubMed ID: 21821799
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antibody targeting to a class I MHC-peptide epitope promotes tumor cell death.
    Wittman VP; Woodburn D; Nguyen T; Neethling FA; Wright S; Weidanz JA
    J Immunol; 2006 Sep; 177(6):4187-95. PubMed ID: 16951384
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recombinant antibodies with MHC-restricted, peptide-specific, T-cell receptor-like specificity: new tools to study antigen presentation and TCR-peptide-MHC interactions.
    Cohen CJ; Denkberg G; Lev A; Epel M; Reiter Y
    J Mol Recognit; 2003; 16(5):324-32. PubMed ID: 14523945
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A therapeutic T cell receptor mimic antibody targets tumor-associated PRAME peptide/HLA-I antigens.
    Chang AY; Dao T; Gejman RS; Jarvis CA; Scott A; Dubrovsky L; Mathias MD; Korontsvit T; Zakhaleva V; Curcio M; Hendrickson RC; Liu C; Scheinberg DA
    J Clin Invest; 2017 Jun; 127(7):2705-2718. PubMed ID: 28628042
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Specificity of bispecific T cell receptors and antibodies targeting peptide-HLA.
    Holland CJ; Crean RM; Pentier JM; de Wet B; Lloyd A; Srikannathasan V; Lissin N; Lloyd KA; Blicher TH; Conroy PJ; Hock M; Pengelly RJ; Spinner TE; Cameron B; Potter EA; Jeyanthan A; Molloy PE; Sami M; Aleksic M; Liddy N; Robinson RA; Harper S; Lepore M; Pudney CR; van der Kamp MW; Rizkallah PJ; Jakobsen BK; Vuidepot A; Cole DK
    J Clin Invest; 2020 May; 130(5):2673-2688. PubMed ID: 32310221
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Selective targeting of melanoma and APCs using a recombinant antibody with TCR-like specificity directed toward a melanoma differentiation antigen.
    Denkberg G; Lev A; Eisenbach L; Benhar I; Reiter Y
    J Immunol; 2003 Sep; 171(5):2197-207. PubMed ID: 12928363
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.